Detection of melanoma relapse:: First comparative analysis on imaging techniques versus S100 protein

被引:34
作者
Beyeler, Mirjam
Waldispuehl, Severa
Strobel, Klaus
Joller-Jemelka, Helen I.
Burg, Guenter
Dummer, Reinhard
机构
[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Nucl Med, CH-8091 Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Clin Immunol, CH-8091 Zurich, Switzerland
关键词
melanoma recurrence; early detection; Serum S100 protein;
D O I
10.1159/000095034
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Background. Early detection of melanoma recurrence is essential for the patient's prognosis. The serum S100 level may be a useful tool to detect relapse early. Objective: To compare the efficacy of imaging techniques and serum S100 in the early detection of melanoma progression. This is the first report of a comparison of a serum marker with an imaging tool in the follow-up of melanoma patients. Methods: From 1992 to 2003, we screened 192 patients suffering from melanoma recurrence after a disease-free interval. Of those, 127 patients were identified whose S100 levels had been assessed parallel to imaging procedures. Results: Serum S100 was elevated in 37% of patients at the time of relapse. In stage III, 32% of the patients had elevated S100 levels whereas in case of progression to stage IV, 48% of the patients presented with increased S100. In 5.5% of patients, S100 was the first indicator of disease progression. Imaging procedures lead to detection of melanoma recurrence in 26.8%. Conclusion: A rising level of serum S100 is a specific and sensitive marker of melanoma progression. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:187 / 191
页数:5
相关论文
共 29 条
[1]
Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma [J].
Abraha, HD ;
Fuller, LC ;
DuVivier, AWP ;
Higgins, EM ;
Sherwood, RA .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 137 (03) :381-385
[2]
Banfalvi Teodora, 2002, Pathology & Oncology Research, V8, P183
[3]
Ultrasound mapping of lymph node and subcutaneous metastases in patients with cutaneous melanoma:: Results of a prospective multicenter study [J].
Blum, A ;
Schmid-Wendtner, MH ;
Mauss-Kiefer, V ;
Eberle, JY ;
Kuchelmeister, C ;
Dill-Müller, D .
DERMATOLOGY, 2006, 212 (01) :47-52
[4]
Bonfrer JMG, 1997, ANTICANCER RES, V17, P2975
[5]
The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma [J].
Bonfrer, JMG ;
Korse, CM ;
Nieweg, OE ;
Rankin, EM .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2210-2214
[6]
Serological markers for melanoma [J].
Brochez, L ;
Naeyaert, JM .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (02) :256-268
[7]
Elevated serum levels of S100 and survival in metastatic malignant melanoma [J].
Buer, J ;
Probst, M ;
Franzke, A ;
Duensing, S ;
Haindl, J ;
Volkenandt, M ;
Wittke, F ;
Hoffmann, R ;
Ganser, A ;
Atzpodien, J .
BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1373-1376
[8]
Serum S100 - A marker for disease monitoring in metastatic melanoma [J].
Dummer, R ;
JollerJemelka, HI ;
Boni, R ;
Burg, G .
DERMATOLOGY, 1997, 194 (03) :208-212
[9]
Swiss guidelines for the treatment and follow-up of cutaneous melanoma [J].
Dummer, R ;
Bösch, U ;
Panizzon, R ;
Bloch, PH ;
Burg, G .
DERMATOLOGY, 2001, 203 (01) :75-80
[10]
Diagnostic value and prognostic significance of protein S-100β, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients [J].
Garbe, C ;
Leiter, U ;
Ellwanger, U ;
Blaheta, HJ ;
Meier, F ;
Rassner, G ;
Schittek, B .
CANCER, 2003, 97 (07) :1737-1745